- Active not recruitingPHASE2
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
This study looks at new ways to treat a type of bladder cancer that hasn't responded to usual treatments. It tests two medicines, TAR-200 and cetrelimab, alone or together, for people who can't or don't want major surgery.
For: Urinary Bladder NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE2
CD8 PET Imaging in Metastatic Solid Tumours
This study looks at a new type of specialised scan for people with advanced cancer. It uses a small amount of a special substance called 89Zr-Df-crefmirlimab to create detailed pictures. This helps doctors see how well a new cancer treatment, called PD-1 antibody therapy, is working.
For: Locally Advanced Solid TumorNetherlands · Spain · United Kingdom - Active not recruitingPHASE3
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
This study looks at new treatments for a type of bladder cancer that hasn't spread into the muscle. It compares new drugs, TAR-200 (alone or with Cetrelimab), against the usual treatment, BCG, to see which works best and is safest.
For: Bladder CancerUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
This study looks at a new combination of two medicines, amivantamab and cetrelimab, for advanced lung cancer. It aims to find the best dose and see how well it works in people whose cancer has spread and who have already had other treatments.
For: Carcinoma, Non-Small-Cell LungUnited States · Brazil · Italy - Active not recruitingPHASE2
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
This study is testing new treatments for a type of bladder cancer called muscle-invasive urothelial carcinoma. Researchers are looking at TAR-200 with cetrelimab, and cetrelimab on its own, to see how well they work against the cancer.
For: Urinary Bladder NeoplasmsUnited States · Belgium · France - Active not recruitingPHASE1, PHASE2
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
This study investigates new ways to treat advanced bladder cancer (urothelial cancer) that has spread or is locally advanced. It combines a drug called erdafitinib, which targets specific cancer changes, with cetrelimab and/or chemotherapy. The aim is to find safe doses and see how well these treatments work.
For: Urothelial CarcinomaUnited States · Belarus · Belgium